Grifois, S.A. - GRFS STOCK NEWS

Welcome to our dedicated page for Grifois, S.A. news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifois, S.A. stock.

Grifols, S.A. (NASDAQ: GRFS) is a leading global healthcare company headquartered in Barcelona, Spain, with a legacy of over 75 years dedicated to improving the health and well-being of people around the world. As a vertically integrated plasma derivative producer, Grifols collects plasma and manufactures life-saving plasma-derived therapies. The company’s commitment to innovation and patient care has established it as a benchmark in the plasma collection market and transfusion medicine.

Grifols operates through three main business divisions:

Bioscience: This division encompasses all plasma-related activities including research, development, collection, production, and sales of plasma-derived therapies. The acquisition of Talecris in 2011 and Biotest in 2022 significantly expanded the product portfolio, with the biopharma business contributing 84% of sales in 2023.
Diagnostic: Providing innovative solutions for safe transfusions, therapy monitoring, and the detection of infectious and autoimmune diseases, this division focuses on research and novel technologies to enhance treatment outcomes and laboratory efficiency.
Hospital: Specializing in non-biological pharmaceutical products, the Hospital division meets the diverse needs of healthcare facilities worldwide.

Grifols' latest advancements include the successful phase 4 trial of XEMBIFY® for primary immunodeficiencies, showing non-inferiority in Ig levels with biweekly dosing compared to weekly dosing. Additionally, the phase 2 trial of ABvac40, a potential Alzheimer’s vaccine, demonstrated a robust immune response and some cognitive benefits in patients with early-stage Alzheimer’s disease.

With a global presence in more than 100 countries, Grifols continues to grow its network of plasma donation centers, boasting over 390 locations across North America, Europe, Africa, the Middle East, and China. The company's economic impact in its core countries of operation was EUR 9.6 billion in 2022, generating 193,000 jobs including indirect and induced employment.

Grifols' class A shares are listed on the Spanish Stock Exchange as part of the Ibex-35 (MCE:GRF), while non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

04/18/2024 09:30 AM

News

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

Rhea-AI Summary

Grifols commemorates five decades of producing life-altering plasma-derived medications for patients at its primary facility in Clayton, North Carolina. The establishment of the Clayton site in 2011 propelled Grifols to become a prominent player in the plasma industry, fostering continuous business expansion. The flagship Grifols campus epitomizes the company's dominance in plasma therapeutics, generating significant positive impact on patient care and medical advancements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.61%

Tags

04/04/2024 04:00 AM

News

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Rhea-AI Summary

Grifols announces CE mark for Procleix ArboPlex Assay, a test to detect major arboviruses in blood donors, enhancing transfusion safety. The test addresses a significant public health concern due to the spread of arboviruses like dengue and Zika. Grifols aims to improve donor screening efficiency and safety with this innovative solution.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.44%

Tags

02/14/2024 03:16 AM

News

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Rhea-AI Summary

Grifols announces positive results from Biotest's phase 3 clinical trial for fibrinogen concentrate BT524, showing efficacy in treating acquired fibrinogen deficiency. The regulatory approval process in Europe and the United States is set to begin in Q4 2024, potentially tapping into an USD 800 million market. Grifols' robust innovation strategy is highlighted, balancing internal and external investments to build a diversified portfolio.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.34%

Tags

11/15/2023 08:00 AM

News

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Rhea-AI Summary

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) completes Cohort 1 of Phase 1/2 study evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15%, a potential breakthrough treatment for alpha1-antitrypsin deficiency. The study aims to demonstrate the effectiveness of a subcutaneous approach compared to intravenous therapy, offering patients the convenience of administering medication from home. This milestone has significant implications for alpha-1 patients, potentially revolutionizing the management of AAT deficiency.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.43%

Tags

11/01/2023 02:46 PM

News

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Rhea-AI Summary

Healthcare software and services company Bloodbuy has entered into an agreement with Cerus Corporation to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) on its online marketplace. IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. The agreement aims to enhance patient outcomes and address inventory challenges in hospitals and blood centers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/24/2023 06:30 PM

News

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Rhea-AI Summary

Araclon Biotech announced positive results from its Phase 2 trial of ABvac40, an active vaccine for the treatment of early-stage Alzheimer's disease. The trial met primary endpoints, confirming the vaccine's safety, tolerability, and robust immune response against the Aβ40 peptide. ABvac40 also showed a 38% reduction in disease progression compared to placebo, as measured by the Mini-Mental State Examination score. The vaccine's unique design targets the C-terminal end of the Aβ40 peptide, potentially preventing harmful reactions and immune triggers. The prevalence of Alzheimer's disease is expected to double by 2050 in the U.S. alone.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.96%

Tags

08/01/2023 08:00 AM

News

Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

Rhea-AI Summary

Grifols (GRF, GRF.P, GRFS) collaborates with Google Cloud to utilize AI technologies, including large language models, to accelerate the development of new biopharma therapeutics. The partnership aims to enhance Grifols' therapeutic pipeline and innovation culture, leveraging AI across the drug development life cycle to reduce time-to-market for novel treatments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.96%

Tags

07/20/2023 08:15 AM

News

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.29%

Tags

07/18/2023 08:00 AM

News

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.68%

Tags

07/13/2023 08:00 AM

News

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Rhea-AI Summary

Grifols has met its enrollment target of 339 patients in the SPARTA clinical trial, which aims to evaluate the efficacy and safety of Grifols' Prolastin®-C in slowing emphysema progression in patients with alpha-1-antitrypsin (AAT) deficiency. The trial is the largest of its kind and will measure the rate of pulmonary-tissue loss over three years. Grifols aims to provide impactful treatment options for alpha-1 patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.42%

Tags

FAQ

What is the current stock price of Grifois, S.A. (GRFS)?

The current stock price of Grifois, S.A. (GRFS) is $7.51 as of December 20, 2024.

What is the market cap of Grifois, S.A. (GRFS)?

The market cap of Grifois, S.A. (GRFS) is approximately 5.2B.

What does Grifols, S.A. specialize in?

Grifols specializes in the collection of plasma and the manufacturing of plasma-derived therapies. It also provides diagnostic solutions and non-biological pharmaceutical products.

Where is Grifols headquartered?

Grifols is headquartered in Barcelona, Spain.

What are the main business divisions of Grifols?

Grifols operates through three main divisions: Bioscience, Diagnostic, and Hospital.

What recent advancements has Grifols made?

Recent advancements include the phase 4 trial of XEMBIFY® for primary immunodeficiencies and the phase 2 trial of ABvac40 for early-stage Alzheimer’s disease.

What is Grifols' market presence?

Grifols has a global presence in more than 100 countries and operates over 390 plasma donation centers.

How has Grifols impacted the economy?

In 2022, Grifols' economic impact was EUR 9.6 billion, generating 193,000 jobs including indirect and induced employment.

Where are Grifols' shares listed?

Grifols' class A shares are listed on the Spanish Stock Exchange as part of the Ibex-35 (MCE:GRF). Non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the NASDAQ through ADRs (NASDAQ:GRFS).

What are the core areas of treatment Grifols focuses on?

Grifols focuses on treating conditions in immunology, hepatology, intensive care, pulmonology, hematology, neurology, and infectious diseases.

What is XEMBIFY®?

XEMBIFY® is a 20% solution of purified human immunoglobulin used for treating primary immunodeficiency diseases.

What is the significance of the ABvac40 trial?

The ABvac40 trial showed a robust immune response and some cognitive benefits in early-stage Alzheimer’s disease, indicating its potential as a therapeutic candidate.